Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14817814 | 0.86 | GRM5 (0.32) | GRM5 | |
| SCHEMBL24253345 | 0.81 | GRM5 (0.45) | GRM5NPC1RAB9ACYP2C19CYP1A2 | |
| SCHEMBL30916103 | 0.77 | RAD52 (0.41) | GRM5NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL5779792 | 0.76 | GRM5 (0.42) | GRM5NPC1RAB9A | |
| SCHEMBL8051769 | 0.75 | GRM5 (0.51) | GRM5NPC1RAB9ACYP2C19CYP1A2 | |
| SCHEMBL209848 | 0.75 | GRM5 (0.51) | GRM5NPC1RAB9ACYP2C19CYP1A2 | |
| SCHEMBL3007282 | 0.74 | GRM5 (0.45) | GRM5NPC1RAB9ACYP2C19CYP1A2 | |
| SCHEMBL25796522 | 0.74 | GRM5 (0.45) | GRM5NPC1RAB9ACYP2C19CYP1A2 | |
| SCHEMBL13019235 | 0.74 | GRM5 (0.50) | GRM5NPC1RAB9ACYP2C19CYP1A2 | |
| SCHEMBL19454341 | 0.74 | GRM5 (0.50) | GRM5NPC1RAB9ACYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936475-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-111936475-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2022103239-A1 | PREPARATION METHOD FOR EDOXABAN TOSYLATE OR HYDRATE THEREOF | 보령제약 주식회사 | 2022-05-19 | — | — | WO | disclosed |
| EP-2266991-B1 | Process for producing thiazole derivative | DAIICHI SANKYO CO LTD (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2602242-B1 | PROCESS FOR PREPARING COMPOUND BY NOVEL SANDMEYER-LIKE REACTION USING NITROXIDE RADICAL COMPOUND AS REACTION CATALYST | DAIICHI SANKYO CO LTD (JP) | 2017-08-23 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| EP-2266991-A2 | Process for producing thiazole derivative | Daiichi Sankyo Company, Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266992-A2 | Process for producing thiazole derivative | Daiichi Sankyo Company, Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-7547786-B2 | 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid; intermediate for compound which exhibits an inhibitory action on an activated coagulation factor X, and which is thus useful as a preventive/therapeutic drug for thrombus-related diseases | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | GRM5 1561/4885NPC1 952/4885RAB9A 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.